pocketful logo
Laurus Labs Ltd logo

Laurus Labs Ltd

NSE: LAURUSLABS BSE: 540222

₹1075.80

(-1.55%)

Fri, 06 Mar 2026, 02:26 pm

mtf coin illustrationMTF 5x

Laurus Labs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    56463.60

  • Net Profit

    354.41

  • P/B

    7.40

  • Sector P/E

    31.98

  • P/E

    92.44

  • EV/EBITDA

    31.60

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    7.36

  • ROCE

    8.80

  • Debt/Equity

    0.62

  • EPS (TTM)

    15.62

  • Dividend Yield

    0.11

  • Book Value

    89.01

  • Interest Cover

    2.98

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (9.6x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (13.4x coverage).
  • Cash flow for Laurus Labs is expected to increase by more than 50% in 2 years time.
  • Laurus Labs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Laurus Labs's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividend payments have increased, but Laurus Labs only paid a dividend in the past 3 years.
  • Whilst dividend payments have been stable, Laurus Labs has been paying a dividend for less than 10 years.
  • Laurus Labs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Laurus Labs's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Laurus Labs's earnings are expected to grow by 18% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters27.4927.5927.5927.6227.62
FII26.5226.1625.7025.5225.56
DII12.4311.7311.9411.7712.74
Public33.5634.5134.7735.0934.08
Government0.000.000.000.000

Read More

Technical Analysis

RSI

49.24

MACD

9.92

50 DMA

1036.50

200 DMA

901.68

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1403.631218.031146.921032.43961.32846.83661.23
Fibonacci1218.031147.131103.331032.43961.53917.73846.83
Camarilla1126.841109.831092.811032.431058.791041.771024.76

Pivots Level: Classic

R3

+371.20

1403.63

R2

+185.60

1218.03

R1

+114.48

1146.92

1032.43
1032.43
Pivot Point
LTP: 1026.20

S1

-71.12

961.32

S2

-185.60

846.83

S3

-371.20

661.23

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1041.98

  • 20-EMA

    1032.88

  • 30-EMA

    1028.76

  • 50-EMA

    1022.95

  • 100-EMA

    991.90

  • 200-EMA

    907.09

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
23 Jan 2026board-meetingsQuarterly Results
23 Oct 2025dividend₹0.80 Dividend /Share31 Oct 2025
01 Oct 2025dividendInterim Dividend - Rs. - 0.831 Oct 2025
15 May 2025agm
24 Apr 2025dividend₹0.80 Dividend /Share09 May 2025
09 Apr 2025dividendInterim Dividend - Rs. - 0.809 May 2025
24 Oct 2024dividend₹0.40 Dividend /Share06 Nov 2024
06 Oct 2024dividendInterim Dividend - Rs. - 0.406 Nov 2024
04 Jun 2024agmAnnual General Meeting05 Jul 2024
25 Apr 2024dividend₹0.40 Dividend /Share08 May 2024

Read More

Peer Comparison

Laurus Labs Ltd logo

Laurus Labs Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Laurus Labs Ltd About

Laurus Labs is equipped with an Active Pharma Ingredients (API).(Source : 202503 Annual Report Page No: 188)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2005

Headquarters

CEO

Ravindranath Kancherla

Employees

Contact

Website icon

Website

http://www.lauruslabs.com

Email icon

Email

secretarial@lauruslabs.com; info@lauruslabs.com

Phone icon

Phone

91-891-3061222

Location icon

Location

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Read More

Laurus Labs Ltd Company History

YearHistory
2020
  • Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States.
  • Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
  • Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market.
2021
  • Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance.
  • Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO.
  • Laurus Labs Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children.
  • Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication.
  • Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences.
2022
  • Laurus Labs received purchase orders from a leading Global Life Sciences Company.
2023
  • Laurus Labs received USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment.
  • Laurus Labs signed Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets.
2024
  • Laurus Labs inaugurates new State of the Art R&D facility at IKP Knowledge park.
  • Laurus Labs concludes successful USFDA Audit for API Manufacturing Facility at Hyderabad.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPSell3689009536.2327 Jan 2025
GRAVITON RESEARCH CAPITAL LLPBuy3690709536.527 Jan 2025
GRAVITON RESEARCH CAPITAL LLPSell6436001011.4803 Aug 2020
GRAVITON RESEARCH CAPITAL LLPBuy6436001011.4103 Aug 2020
AVNI PARESH SHAHSell936470511.7629 Jun 2020
SETU SECURITIES PVT LTDBuy50317519.7629 Jun 2020
AVNI PARESH SHAHBuy52341513.329 Jun 2020
MILLENNIUM STOCK BROKING PVT LTDBuy52448513.2129 Jun 2020
BNP PARIBAS ARBITRAGEBuy1500000504.2529 Jun 2020
SETU SECURITIES PVT LTDSell268011506.9229 Jun 2020

Read More

Laurus Labs Ltd News

Laurus Labs Block Trade Worth Rs. 59.98 Crores

Laurus Labs witnessed a significant block trade on NSE worth Rs. 59.98 crores involving 563,347 shares at Rs. 1064.70 per share, indicating substantial institutional activity.

02 Mar 2026

co actions results

Laurus Labs Gets NCLT Approval for Subsidiary Restructuring

NCLT Amaravati approves Laurus Labs' composite scheme for demerger of LSPL unit and amalgamation with subsidiaries. Creditor meetings scheduled for April 06, 2026.

24 Feb 2026

co actions results

Laurus Labs Featured in S&P Global Sustainability Yearbook

Laurus Labs achieves S&P Global CSA score of 81/100, earning recognition in 2026 Sustainability Yearbook among 848 companies worldwide out of 9,200 assessed globally.

23 Feb 2026

stocks

Mirae Asset Mutual Fund Increases Stake in Laurus Labs

Mirae Asset Mutual Fund acquired additional 111,064 shares of Laurus Labs through open market transactions on February 18, 2026, increasing its holding from 4.01% to 4.03%.

20 Feb 2026

co actions results

Laurus Labs Block Trade Worth Rs. 59.97 Crores

Laurus Labs witnessed a significant NSE block trade worth Rs. 59.97 crores involving approximately 593,935 shares at Rs. 1009.70 per share, indicating substantial institutional activity.

27 Jan 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800